Associated British Foods Acquires Fytexia from ArchiMed
February 2, 2022
Associated British Foods (ABF) has acquired French health-ingredients developer Fytexia from transatlantic private equity firm ArchiMed (MED I fund). The deal, which will fold Fytexia into ABF’s ABF Ingredients division, follows strong revenue and profit growth under ArchiMed’s ownership and returns MED I roughly four times its investment.
- Buyers
- Associated British Foods
- Targets
- Fytexia
- Sellers
- ArchiMed, MED I fund (ArchiMed)
- Industry
- Food & Beverage
- Location
- France
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Nactarome Group Acquires Plantex SAS
October 16, 2025
Food & Beverage
Nactarome Group, majority owned by private equity firm TA Associates, has acquired Plantex SAS, a French producer of high-quality plant extracts for the food, nutraceutical, cosmetics and animal nutrition markets. The deal is an add-on to Nactarome’s ingredient platform to expand its plant-extraction capabilities and product offering; terms were not disclosed.
-
ARCHIMED Acquires FIM Medical
October 15, 2024
Medical Devices
ARCHIMED, a healthcare-focused private equity firm, has acquired FIM Medical, a Lyon-based leader in occupational health medical devices specializing in vision testers, audiometers and spirometers. The acquisition, executed by ARCHIMED's MED Rise fund, positions the firm to strengthen its neuro & sensory and occupational health capabilities and support FIM Medical's international expansion.
-
biote Corp Acquires Asteria Health
January 17, 2024
Healthcare Services
biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.
-
ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA
November 18, 2021
Pharmaceuticals
Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.
-
ARCHIMED-backed Fytexia Acquires B Natural
June 1, 2021
Food & Beverage
Fytexia, the ARCHIMED-owned health ingredients developer, has acquired Milan-based B Natural, a European leader in the extraction and refinement of propolis for health ingredients. The add-on strengthens Fytexia's product portfolio and R&D capabilities, expands its geographic reach, and is expected to boost group sales by about 40 percent.
-
ARCHIMED Acquires Majority Stake in Germany's Zyto Group
January 12, 2021
Medical Devices
ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.